Clinical Updates in CSPC
Post-Hoc Analyses of Phase 3 ARCHES Trial: OS in Patients With mHSPC Who Received Prior ADT and Reached Low PSA Levels Treated Further With Enzalutamide
By
Yale Cancer Center
FEATURING
Daniel Petrylak
By
Yale Cancer Center
FEATURING
Daniel Petrylak
Login to view comments.
Click here to Login
